LABELS · 15eaa42c-d1e7-5c08-e063-6394a90ae469

Cortrosyn

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-04-12
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS AND USAGE CORTROSYN ® (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal CORTROSYN ® test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison’s disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan’s syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal CORTROSYN ® test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison’s disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency.

Full extracted label fields

application numbers

NDA016750

boxed warning exact

brand names

Cortrosyn

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15eaaab2-d656-7310-e063-6394a90ae59f

generic names

COSYNTROPIN

15eaa42c-d1e7-5c08-e063-6394a90ae469

indications and usage exact

INDICATIONS AND USAGE CORTROSYN ® (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal CORTROSYN ® test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison’s disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan’s syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal CORTROSYN ® test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison’s disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency.

indications and usage tables exact

is original packager

manufacturer names

Medical Purchasing Solutions, LLC

matched search terms

tumors

package ndcs

71872-7318-1

product ndcs

71872-7318

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAMUSCULAR
INTRAVENOUS

rxcuis

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 379
end exclusive: true
exact text: INDICATIONS AND USAGE CORTROSYN ® (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 veni
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 0

current approval status

not_reconciled

duplicate text group

dup-f447cc94b4a27c2e5c87

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-288ebede02d6bc4dc6f2

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 179
end exclusive: true
exact text: INDICATIONS AND USAGE CORTROSYN ® (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 2 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 629
end exclusive: true
exact text: INDICATIONS AND USAGE CORTROSYN ® (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suff
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 0

current approval status

not_reconciled

duplicate text group

dup-feafd7945b77199938e8

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-9d3f66171a88002bdc86

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 429
end exclusive: true
exact text: Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section).
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 180

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 855
end exclusive: true
exact text: it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 230

current approval status

not_reconciled

duplicate text group

dup-0ec47a68eb48d023503f

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-995d567b064817068872

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 655
end exclusive: true
exact text: Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 430

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 985
end exclusive: true
exact text: pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 456

current approval status

not_reconciled

duplicate text group

dup-c42a504bde98d988ba45

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-26def92050f6a9469220

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 785
end exclusive: true
exact text: Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 656

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1129
end exclusive: true
exact text: of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal CORTROSYN ® test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison’s
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 586

current approval status

not_reconciled

duplicate text group

dup-36918056d9e9e31f0f84

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-2ceaa919a6eee3176a59

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 929
end exclusive: true
exact text: For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 786

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · positive indication candidate

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1288
end exclusive: true
exact text: will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal CORTROSYN ® test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison’s disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 730

current approval status

not_reconciled

duplicate text group

dup-e441f3859ac801a93ae7

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-bf0ad2dd70df506d6f12

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

end: 1044
end exclusive: true
exact text: is diagnosed by a subnormal CORTROSYN ® test, further studies are indicated
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 969

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1088
end exclusive: true
exact text: When presumptive adrenal insufficiency is diagnosed by a subnormal CORTROSYN ® test, further studies are indicated to determine if it is primary or secondary.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 930

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1424
end exclusive: true
exact text: d to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal CORTROSYN ® test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison’s disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 889

current approval status

not_reconciled

duplicate text group

dup-30c16648f2fc9c3fcf57

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-46f3b00026f181d654dd

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1224
end exclusive: true
exact text: Primary adrenal insufficiency (Addison’s disease) is the result of an intrinsic disease process, such as tuberculosis within the gland.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1089

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1526
end exclusive: true
exact text: udies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison’s disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of cortic
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1025

current approval status

not_reconciled

duplicate text group

dup-1bf5c88b9966d22f31d8

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-3dcc9cf88a2b42fbc813

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1326
end exclusive: true
exact text: The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism).
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1225

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1672
end exclusive: true
exact text: ’s disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan’s syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1127

current approval status

not_reconciled

duplicate text group

dup-985f0db2d03b5da5097e

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-cca5a955122703592a8d

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1472
end exclusive: true
exact text: Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1327

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1796
end exclusive: true
exact text: icient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan’s syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respon
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1273

current approval status

not_reconciled

duplicate text group

dup-53873ae8fd7c4b4a9dde

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-fb13e933fcf3e249038d

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1596
end exclusive: true
exact text: It is commonly seen, for example, as result of corticosteroid therapy, Sheehan’s syndrome and pituitary tumors or ablation.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1473

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2032
end exclusive: true
exact text: production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan’s syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal CORTROSYN ® test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Sugge
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1397

current approval status

not_reconciled

duplicate text group

dup-c4975868adf3a5b7eaba

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-1696e451c692f39b8a60

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1832
end exclusive: true
exact text: The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1597

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2226
end exclusive: true
exact text: based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal CORTROSYN ® test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison’s diseas
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1633

current approval status

not_reconciled

duplicate text group

dup-b8eb2fd9bedfac7c5456

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-5eee42af086c92b24e3f

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

context exact
atment with Repository Corticotropin Injection USP and then retested.
kind
biomarker
polarity
not_inferred
span
end
2025
end exclusive
true
exact text
retested
label id
15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start
2017

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2026
end exclusive: true
exact text: Patients selected for further study as the result of a subnormal CORTROSYN ® test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1833

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2322
end exclusive: true
exact text: ACTH. Patients selected for further study as the result of a subnormal CORTROSYN ® test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison’s disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficienc
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1827

current approval status

not_reconciled

duplicate text group

dup-f3b6c1970b31af382339

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-4756808e33f24ce1c5e9

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2122
end exclusive: true
exact text: Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 2027

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · unclassified context

application numbers

NDA016750

brand names

Cortrosyn

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2324
end exclusive: true
exact text: e given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison’s disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 1923

current approval status

not_reconciled

duplicate text group

dup-d2ba41c8e77b92981ec3

extraction review status

automated_candidate_pending_source_review

generic names

COSYNTROPIN

ind-span-68bc9de33789132659ea

label id

15eaa42c-d1e7-5c08-e063-6394a90ae469

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2324
end exclusive: true
exact text: Under these conditions little or no increase in plasma cortisol levels will be seen in Addison’s disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency.
label id: 15eaa42c-d1e7-5c08-e063-6394a90ae469
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5812698d47c80344fe6f21f22907a3c15a100ca6458841f475b9dea9369c511f
start: 2123

source url

https://api.fda.gov/drug/label.json?search=id%3A%2215eaa42c-d1e7-5c08-e063-6394a90ae469%22

spl effective date

2024-04-12

spl set id

15eaaab2-d656-7310-e063-6394a90ae59f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice